MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2022


	Shares			Weighted Average Grant Date Fair Value
Unvested balance at January 1, 2022		58,333		$	1.80
Vested		(58,333	)		1.80
Unvested balance at June 30, 2022		—		$	—

Schedule of Warrant Exercised


	Warrants Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
Balance at January 1, 2022		1,311,117		$	4.03		7.30
Exercised		(608,612	)		1.80
Balance at June 30, 2022		702,505		$	5.97		5.74

Summary of Activity and Information regarding Outstanding and Exercisable Options

The following table summarizes the activity and information regarding MAIA's outstanding and exercisable options for the six months ended June 30, 2022:


	Options Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Balance at January 1, 2022		5,797,185		$	2.22		8.59		—
Granted		173,726			9.00
Exercised		(26,500	)		1.80
Cancelled/forfeited		(16,888	)		1.82
Balance at June 30, 2022		5,927,523		$	2.43		8.15			$	17,273,195
Options exercisable at June 30, 2022		5,223,220		$	2.10		8.04			$	16,011,367

Assumptions used in Calculating Value of Options Granted

The value of option grants is calculated using the Black-Scholes option pricing model with the following assumptions for options granted during the six months ended June 30:


	2022		2021
Risk-free interest rate	2.14%- 3.06%		0.36% - 1.05%
Expected term (in years)	5 - 6.25		5 – 6.50
Expected volatility	72.0% - 75.4%		74.3% - 81.5%
Expected dividend yield		—		—

Summary of Stock Based Compensation Expense

Stock based compensation related to the Company’s stock plans are as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2022		2021		2022		2021
General and administrative	$	358,313	$	447,401	$	798,866	$	935,138
Research and development		226,455		329,731		499,232		395,186
Total stock-based compensation	$	584,768	$	777,132	$	1,298,098	$	1,330,324